CA2907832A1 - Antibacterial biaromatic derivatives - Google Patents

Antibacterial biaromatic derivatives

Info

Publication number
CA2907832A1
CA2907832A1 CA2907832A CA2907832A CA2907832A1 CA 2907832 A1 CA2907832 A1 CA 2907832A1 CA 2907832 A CA2907832 A CA 2907832A CA 2907832 A CA2907832 A CA 2907832A CA 2907832 A1 CA2907832 A1 CA 2907832A1
Authority
CA
Canada
Prior art keywords
oxo
oxazolidin
pyrido
methoxy
oxazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2907832A
Other languages
English (en)
French (fr)
Inventor
Sylvaine Cren
Astrid FRIEDLI
Christian Hubschwerlen
Georg Rueedi
Cornelia Zumbrunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CA2907832A1 publication Critical patent/CA2907832A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2907832A 2013-04-16 2014-04-15 Antibacterial biaromatic derivatives Abandoned CA2907832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2013053021 2013-04-16
IBPCT/IB2013/053021 2013-04-16
PCT/IB2014/060724 WO2014170821A1 (en) 2013-04-16 2014-04-15 Antibacterial biaromatic derivatives

Publications (1)

Publication Number Publication Date
CA2907832A1 true CA2907832A1 (en) 2014-10-23

Family

ID=50639826

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2907832A Abandoned CA2907832A1 (en) 2013-04-16 2014-04-15 Antibacterial biaromatic derivatives

Country Status (21)

Country Link
US (1) US9527867B2 (enExample)
EP (1) EP2986607B1 (enExample)
JP (1) JP6375365B2 (enExample)
KR (1) KR20150143720A (enExample)
CN (1) CN105143216B (enExample)
AR (1) AR095884A1 (enExample)
AU (1) AU2014255326B2 (enExample)
BR (1) BR112015026261A8 (enExample)
CA (1) CA2907832A1 (enExample)
CL (1) CL2015003019A1 (enExample)
EA (1) EA029361B1 (enExample)
ES (1) ES2640482T3 (enExample)
HK (1) HK1221459A1 (enExample)
MA (1) MA38588B1 (enExample)
MX (1) MX362338B (enExample)
PH (1) PH12015502411A1 (enExample)
PL (1) PL2986607T3 (enExample)
SA (1) SA515361261B1 (enExample)
SG (1) SG11201508479RA (enExample)
TW (1) TWI631119B (enExample)
WO (1) WO2014170821A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4833385B1 (ja) 2008-10-07 2011-12-07 アクテリオン ファーマシューティカルズ リミテッド 三環式オキサゾリジノン抗生物質化合物
AR102256A1 (es) * 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi
UY36851A (es) 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
TW201808906A (zh) 2016-03-16 2018-03-16 拜耳作物科學股份有限公司 作為殺蟲劑之經取代吡啶化合物
AR108108A1 (es) 2016-04-14 2018-07-18 Idorsia Pharmaceuticals Ltd Derivados biaromáticos antibacterianos con sustitución de oxetan-3-iloxi
GB2550437B (en) * 2016-05-20 2021-06-23 Bugworks Res Inc Heterocyclic compounds useful as anti-bacterial agents and method for production
TW201833120A (zh) * 2017-02-17 2018-09-16 瑞士商愛杜西亞製藥有限公司 芳基噁唑啶酮抗生素化合物
EP3284739A1 (de) 2017-07-19 2018-02-21 Bayer CropScience Aktiengesellschaft Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel
CN111527093B (zh) * 2017-11-29 2023-06-09 巴格沃克斯研究有限公司 抗菌杂环化合物及其合成
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
PH12022550339A1 (en) 2019-09-12 2023-03-13 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
EP4126855B1 (en) * 2020-03-24 2024-04-24 F. Hoffmann-La Roche AG Compounds and their use in the treatment of bacterial infections
CN115785718B (zh) * 2022-11-25 2023-08-22 四川大学 一种多基底表面的金属配位抗菌涂层及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0297042A1 (de) 1987-06-23 1988-12-28 Ciba-Geigy Ag Substituierte Penem-Verbindungen
DE19802239A1 (de) 1998-01-22 1999-07-29 Bayer Ag Neue mit Bicyclen substituierte Oxazolidinone
AU1026901A (en) 1999-10-29 2001-05-08 Syngenta Participations Ag Novel herbicides
AU2002347985A1 (en) 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
AR040335A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
US20090186834A1 (en) 2005-03-24 2009-07-23 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
EP2141154A4 (en) 2007-03-30 2011-06-01 Inst Med Molecular Design Inc OXAZOLIDINONE DERIVATIVITY WITH HEMMETIC EFFECT ON TYPE I 11-HYDROXYSTEROIDDEHYDROGENASE
CL2008001003A1 (es) * 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi
BRPI0907892A2 (pt) 2008-02-20 2015-07-28 Actelion Pharmaceuticals Ltd Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
CA2713187C (en) 2008-02-22 2016-06-07 Actelion Pharmaceuticals Ltd Oxazolidinone derivatives
WO2010015985A1 (en) * 2008-08-04 2010-02-11 Actelion Pharmaceuticals Ltd Tricyclic alkylaminomethyloxazolidinone derivatives
JP4833385B1 (ja) 2008-10-07 2011-12-07 アクテリオン ファーマシューティカルズ リミテッド 三環式オキサゾリジノン抗生物質化合物
ES2395491T3 (es) 2008-10-10 2013-02-13 Actelion Pharmaceuticals Ltd. 2-Benzotiofenil y 2-naftil-oxazolidinonas y sus análogos azaisósteros como agentes antibacterianos
IN2014CN04126A (enExample) 2011-11-08 2015-07-10 Actelion Pharmaceuticals Ltd

Also Published As

Publication number Publication date
MA38588B1 (fr) 2018-04-30
KR20150143720A (ko) 2015-12-23
EP2986607B1 (en) 2017-06-14
BR112015026261A2 (pt) 2017-07-25
WO2014170821A1 (en) 2014-10-23
PL2986607T3 (pl) 2017-11-30
US20160075722A1 (en) 2016-03-17
TWI631119B (zh) 2018-08-01
AR095884A1 (es) 2015-11-18
TW201516043A (zh) 2015-05-01
EA029361B1 (ru) 2018-03-30
EP2986607A1 (en) 2016-02-24
AU2014255326B2 (en) 2018-09-13
EA201501025A1 (ru) 2016-08-31
SA515361261B1 (ar) 2016-06-15
ES2640482T3 (es) 2017-11-03
MX2015014576A (es) 2016-03-04
JP6375365B2 (ja) 2018-08-15
BR112015026261A8 (pt) 2017-12-26
PH12015502411A1 (en) 2016-02-22
MX362338B (es) 2019-01-11
JP2016516805A (ja) 2016-06-09
US9527867B2 (en) 2016-12-27
SG11201508479RA (en) 2015-11-27
AU2014255326A1 (en) 2015-11-26
MA38588A1 (fr) 2017-05-31
CN105143216B (zh) 2018-04-13
CN105143216A (zh) 2015-12-09
HK1221459A1 (zh) 2017-06-02
CL2015003019A1 (es) 2016-09-30

Similar Documents

Publication Publication Date Title
US9527867B2 (en) Antibacterial biaromatic derivatives
KR20210124296A (ko) 면역조절제, 조성물 및 이의 방법
US9850256B2 (en) Antibacterial basic biaromatic derivatives with aminoalkoxy substitution
WO2018215668A1 (en) Novel inhibitors of map4k1
AU2012293329A1 (en) Quinazoline-2,4-dione derivatives
AU2013283993A1 (en) Novel fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors
EP1981881A1 (en) Tetrahydropyrane antibiotics
AU2022305807B2 (en) Pyrimidine compounds for use as map4k1 inhibitors
US9487516B2 (en) Antibacterial oxadiazolone derivatives
TW201429972A (zh) 抗菌噁唑酮衍生物
CA3020570A1 (en) Antibacterial biaromatic derivatives with oxetane-3-yloxy substitution

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190412

FZDE Discontinued

Effective date: 20220808